Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/188909
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Medina Gutiérrez, Esperanza | - |
dc.contributor.author | Céspedes, María Virtudes | - |
dc.contributor.author | Gallardo, Alberto | - |
dc.contributor.author | Rioja Blanco, Elisa | - |
dc.contributor.author | Pavón, Miquel Àngel | - |
dc.contributor.author | Asensio Puig, Laura | - |
dc.contributor.author | Farré, Lourdes | - |
dc.contributor.author | Alba Castellón, Lorena | - |
dc.contributor.author | Unzueta, Ugutz | - |
dc.contributor.author | Villaverde, Antonio | - |
dc.contributor.author | Vázquez, Esther | - |
dc.contributor.author | Casanova, Isolda | - |
dc.contributor.author | Mangues, Ramon | - |
dc.date.accessioned | 2022-09-12T10:27:00Z | - |
dc.date.available | 2022-09-12T10:27:00Z | - |
dc.date.issued | 2022-07-12 | - |
dc.identifier.issn | 2227-9059 | - |
dc.identifier.uri | http://hdl.handle.net/2445/188909 | - |
dc.description.abstract | Advanced endometrial cancer (EC) lacks therapy, thus, there is a need for novel treatment targets. CXCR4 overexpression is associated with a poor prognosis in several cancers, whereas its inhibition prevents metastases. We assessed CXCR4 expression in EC in women by using IHC. Orthotopic models were generated with transendometrial implantation of CXCR4-transduced EC cells. After in vitro evaluation of the CXCR4-targeted T22-GFP-H6 nanocarrier, subcutaneous EC models were used to study its uptake in tumor and normal organs. Of the women, 91% overexpressed CXCR4, making them candidates for CXCR4-targeted therapies. Thus, we developed CXCR4(+) EC mouse models to improve metastagenesis compared to current models and to use them to develop novel CXCR4-targeted therapies for unresponsive EC. It showed enhanced dissemination, especially in the lungs and liver, and displayed 100% metastasis penetrance at all clinically relevant sites with anti-hVimentin IHC, improving detection sensitivity. Regarding the CXCR4-targeted nanocarrier, 60% accumulated in the SC tumor; therefore, selectively targeting CXCR4(+) cancer cells, without toxicity in non-tumor organs. Our CXCR4(+) EC models will allow testing of novel CXCR4-targeted drugs and development of nanomedicines derived from T22-GFP-H6 to deliver drugs to CXCR4(+) cells in advanced EC. This novel approach provides a therapeutic option for women with metastatic, high risk or recurrent EC that have a dismal prognosis and lack effective therapies. | - |
dc.format.extent | 18 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI AG | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/biomedicines10071680 | - |
dc.relation.ispartof | Biomedicines, 2022, vol. 10, num. 7, p. 1680 | - |
dc.relation.uri | https://doi.org/10.3390/biomedicines10071680 | - |
dc.rights | cc by (c) Medina Gutiérrez, Esperanza et al., 2022 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Càncer d'endometri | - |
dc.subject.classification | Metàstasi | - |
dc.subject.other | Endometrial cancer | - |
dc.subject.other | Metastasis | - |
dc.title | Novel Endometrial Cancer Models Using Sensitive Metastasis Tracing for CXCR4-Targeted Therapy in Advanced Disease | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2022-08-16T10:02:56Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 35884987 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
biomedicines-10-01680-v4.pdf | 3.41 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License